1072 related articles for article (PubMed ID: 26003804)
21. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
22. Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Rovers KP; Bakkers C; Simkens GAAM; Burger JWA; Nienhuijs SW; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; Ayez N; de Boer NL; van Meerten E; Tuynman JB; Kusters M; Sluiter NR; Verheul HMW; van der Vliet HJ; Wiezer MJ; Boerma D; Wassenaar ECE; Los M; Hunting CB; Aalbers AGJ; Kok NFM; Kuhlmann KFD; Boot H; Chalabi M; Kruijff S; Been LB; van Ginkel RJ; de Groot DJA; Fehrmann RSN; de Wilt JHW; Bremers AJA; de Reuver PR; Radema SA; Herbschleb KH; van Grevenstein WMU; Witkamp AJ; Koopman M; Haj Mohammad N; van Duyn EB; Mastboom WJB; Mekenkamp LJM; Nederend J; Lahaye MJ; Snaebjornsson P; Verhoef C; van Laarhoven HWM; Zwinderman AH; Bouma JM; Kranenburg O; van 't Erve I; Fijneman RJA; Dijkgraaf MGW; Hemmer PHJ; Punt CJA; Tanis PJ; de Hingh IHJT; ;
BMC Cancer; 2019 Apr; 19(1):390. PubMed ID: 31023318
[TBL] [Abstract][Full Text] [Related]
23. [Rationality of performing hyperthermic intraperitoneal chemotherapy 5-8 weeks after primary tumor resection for patients with locally advanced colorectal cancer-based on COLOPEC].
Lei ZY; Guan TP; Luo JL; Tang HS; Cui SZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Dec; 22(12):1115-1117. PubMed ID: 31874525
[TBL] [Abstract][Full Text] [Related]
24. Laparoscopic HIPEC for Peritoneal Carcinomatosis from Gastric Cancer - Technique and Early Outcomes of Our First Cases.
Bălescu I; Godoroja D; Gongu M; Tomulescu V; Copăescu C
Chirurgia (Bucur); 2017; 112(6):714-725. PubMed ID: 29288614
[TBL] [Abstract][Full Text] [Related]
25. Primary curative surgery and preemptive or adjuvant hyperthermic peritoneal chemotherapy in colorectal cancer patients at high risk to develop peritoneal carcinomatosis. A systematic review.
Stamou K; Gouvas N; Pechlivanides G; Xynos E
J BUON; 2018; 23(5):1249-1261. PubMed ID: 30570844
[TBL] [Abstract][Full Text] [Related]
26. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
[TBL] [Abstract][Full Text] [Related]
27. Preliminary results of prophylactic HIPEC in patients with locally advanced gastric cancer.
Graziosi L; Cantarella F; Mingrone E; Gunnellini M; Cavazzoni E; Liberati M; Donini A
Ann Ital Chir; 2013; 84(5):551-6. PubMed ID: 24140896
[TBL] [Abstract][Full Text] [Related]
28. Patterns of recurrence following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
Braam HJ; van Oudheusden TR; de Hingh IH; Nienhuijs SW; Boerma D; Wiezer MJ; van Ramshorst B
J Surg Oncol; 2014 Jun; 109(8):841-7. PubMed ID: 24619813
[TBL] [Abstract][Full Text] [Related]
29. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
Pereira F; Serrano A; Manzanedo I; Pérez-Viejo E; González-Moreno S; González-Bayón L; Arjona-Sánchez A; Torres J; Ramos I; Barrios ME; Cascales P; Morales R; Boldó E; García-Fadrique A; Arteaga X; Gutierrez-Calvo A; Sánchez-García S; Asensio E; Ramírez CP; Artiles M; Vaqué J; Parra PA; Villarejo P; Muñoz-Casares C; Turienzo E; Calero A; Torrejimeno IJ; Prieto I; Galindo J; Borrego V; Marcello ME; Rihuete C; Carrasco J; Gomez-Quiles L
BMC Cancer; 2022 May; 22(1):536. PubMed ID: 35549912
[TBL] [Abstract][Full Text] [Related]
30. Second-look surgery plus hyperthermic intraperitoneal chemotherapy for patients with colorectal cancer at high risk of peritoneal carcinomatosis: Does it really save lives?
Cortes-Guiral D; Elias D; Cascales-Campos PA; Badía Yébenes A; Guijo Castellano I; León Carbonero AI; Martín Valadés JI; Garcia-Foncillas J; Garcia-Olmo D
World J Gastroenterol; 2017 Jan; 23(3):377-381. PubMed ID: 28210074
[TBL] [Abstract][Full Text] [Related]
31. Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
Glockzin G; von Breitenbuch P; Schlitt HJ; Piso P
J Surg Oncol; 2013 May; 107(6):574-8. PubMed ID: 22833286
[TBL] [Abstract][Full Text] [Related]
32. Cytoreduction and hyperthermic intraperitoneal chemotherapy: a feasible and effective option for colorectal cancer patients after emergency surgery in the presence of peritoneal carcinomatosis.
van Oudheusden TR; Braam HJ; Nienhuijs SW; Wiezer MJ; van Ramshorst B; Luyer MD; Lemmens VE; de Hingh IH
Ann Surg Oncol; 2014 Aug; 21(8):2621-6. PubMed ID: 24671638
[TBL] [Abstract][Full Text] [Related]
33. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients.
Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2013 Dec; 68(6):551-8. PubMed ID: 24193287
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
[TBL] [Abstract][Full Text] [Related]
35. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
36. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from colorectal cancer.
Gervais MK; Dubé P; McConnell Y; Drolet P; Mitchell A; Sideris L
J Surg Oncol; 2013 Dec; 108(7):438-43. PubMed ID: 24018983
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
Verwaal VJ; van Ruth S; de Bree E; van Sloothen GW; van Tinteren H; Boot H; Zoetmulder FA
J Clin Oncol; 2003 Oct; 21(20):3737-43. PubMed ID: 14551293
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study.
Yu P; Ye Z; Dai G; Zhang Y; Huang L; Du Y; Cheng X
BMC Cancer; 2020 Nov; 20(1):1108. PubMed ID: 33198674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
